Treatment of Post-Neurosurgical Ventriculitis and Scalp Infection Caused by Klebsiella pneumoniae Carbapenemase and New Delhi Metallo-β-Lactamase Co-Producing Carbapenem-Resistant Klebsiella pneumoniae: A Case Report
Abstract
The treatment of intracranial infections caused by Klebsiella pneumoniae carbapenemase and New Delhi metallo-β-lactamase coproducing carbapenem-resistant Klebsiella pneumoniae is extremely limited. The blood-brain barrier severely restricts the penetration of most systemically administered antibiotics, and robust pharmacokinetic/pharmacodynamic data for novel agents in the central nervous system remain scarce. Therefore, identifying effective therapeutic strategies is critical. We report a study of a 36-year-old Han Chinese male treated with meropenem-vaborbactam and aztreonam in the case of post-neurosurgical ventriculitis and scalp infection caused by Kleb sie lla pneumonia e carbapenemase and New Delhi metallo-β-lactamase co-producing carbapenem-resistant Klebsiella pneumoniae. Meanwhile, we also examined the plasma and cerebrospinal fluid concentrations of meropenem-vaborbactam at 0, 1, 2, 3, 5, and 8 h over a complete dosing interval. Pharmacokinetic analysis was as follows: for meropenem and vaborbactam, the plasma concentrations were 0.75-36.33 mg/L and 4.57-94.71 mg/L, respectively, while those in cerebrospinal fluid ranged from 1.04 to 4.66 mg/L and 3.29 to 16.11 mg/L, respectively. Calculated cerebrospinal fluid penetration reached 19.0% for meropenem and 21.2% for vaborbactam. This work further emphasizes the significance of therapeutic drug monitoring in clinical practice in order to optimize antibiotic therapy in severe infections.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.